Cerebral adrenoleukodystrophy (CALD): cross-border specialty drug access for international patients

Quick orientation

X-linked adrenoleukodystrophy affects approximately 1 in 17,000 males. The cerebral form (CALD) occurs in approximately 35 to 40 percent of affected boys, typically with onset between ages 3 and 12.

Typical age of onset. Cerebral form most commonly between ages 3 and 12. Adrenal insufficiency can present at any age and may precede neurologic symptoms.

Severity tiers. Untreated, the cerebral form is progressive and rapidly fatal. Early intervention before significant neurologic decline is essential, which is why newborn screening for ALD is being adopted in a growing number of jurisdictions.

Why specialty drugs for Cerebral adrenoleukodystrophy (CALD) are hard to access internationally

Skysona (elivaldogene autotemcel) is the first ex vivo gene therapy approved by the FDA for early CALD (2022). It requires treatment at qualified centers and a narrow eligibility window based on MRI Loes score and neurologic function. Newborn screening for ALD is rolling out unevenly globally, which means many international families are diagnosed late and miss the gene-therapy window.

Treatments approved by the FDA

• Skysona (elivaldogene autotemcel) — FDA approval: 2022. Mechanism: Autologous ex vivo gene therapy adding functional ABCD1. Route: One-time intravenous infusion of modified autologous cells. US WAC ballpark: Approximately USD 3.0 million one-time. Country pricing: UAE · Saudi Arabia · Qatar · Kuwait · Egypt · Jordan.

Cross-border pathways used for Cerebral adrenoleukodystrophy (CALD)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Medical Tourism Access
• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease

What your physician needs to know

• MRI Loes score and neurologic function determine eligibility for gene therapy.
• ABCD1 variant confirmation is required.
• Adrenal function (cortisol, ACTH) should be checked; many boys have or develop adrenal insufficiency.
• Allogeneic hematopoietic stem cell transplant remains a comparator pathway; the treating center counsels on both.
• Time-to-treatment is critical given disease progression; delays in international referral can compromise eligibility.

Common questions

Can my son receive Skysona abroad?

Skysona is administered at qualified US treatment centers. Reserve Meds supports the medical-tourism pathway, including travel logistics and documentation.

How does Skysona compare to bone marrow transplant?

Both are one-time interventions intended to halt cerebral disease progression. Skysona avoids the need for a matched donor. The treating center counsels on the specific case.

What is the eligibility window?

Boys aged 4 to 17 with early cerebral disease (specific MRI Loes score range) and limited neurologic involvement at the time of treatment. Your treating center confirms.

What happens if my son is diagnosed late?

Late-stage disease may not be eligible for gene therapy. We help families connect with comparator pathways and supportive care.

Who pays for medical tourism?

Reserve Meds operates cash-pay. Some families combine personal funds with foundation support and disease-specific charity programs.

How long is the program?

From referral to discharge typically 3 to 6 months at the treatment center.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Cerebral adrenoleukodystrophy (CALD), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Cerebral adrenoleukodystrophy (CALD)

Reserved for you.